{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:50:41Z","timestamp":1793987441036,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtct.2022.04.011","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T13:05:55Z","timestamp":1652706355000},"page":"376-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents\/Young Adults With CML in the TKI Era"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-3222","authenticated-orcid":false,"given":"Hiroyuki","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-2508","authenticated-orcid":false,"given":"Akihiko","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-2894","authenticated-orcid":false,"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-3995","authenticated-orcid":false,"given":"Naoki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-4066","authenticated-orcid":false,"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Hashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.04.011_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jtct.2022.04.011_bib0003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2022.04.011_bib0004","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/cancers13164102","article-title":"Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the international registry of childhood cml","volume":"13","author":"Millot","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2022.04.011_bib0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"32","author":"Millot","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the Prospective Trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin P\u00e4diatrie"},{"key":"10.1016\/j.jtct.2022.04.011_bib0008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in children and young adults with chronic myeloid leukemia: a CIBMTR cohort analysis","volume":"22","author":"Chaudhury","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3109\/10428194.2015.1065981","article-title":"Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy","volume":"57","author":"Brogile","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.04.011_bib0011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0012","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0013","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705478","article-title":"Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia","volume":"38","author":"Krejci","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/leu.2008.401","article-title":"Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase","volume":"23","author":"Luo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.011_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00277-011-1349-2","article-title":"Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients","volume":"91","author":"Topcuoglu","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0016","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis","volume":"47","author":"Khoury","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0017","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","article-title":"Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia","volume":"2","author":"Chhabra","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.011_bib0018","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0019","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00277-017-3021-y","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia","volume":"96","author":"Zhao","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1705190","article-title":"The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter","volume":"36","author":"Ruiz-Arg\u00fcelles","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0021","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0022","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.04.011_bib0023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0026","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors1","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2022.04.011_bib0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0029","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0030","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0031","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog\u2013containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0032","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0033","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/pbc.24922","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia","volume":"61","author":"Kato","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2022.04.011_bib0034","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood-2014-10-604702","article-title":"Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia","volume":"125","author":"Kato","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0036","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavl\u016f","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0037","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0038","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0039","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0041","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-019-02627-9","article-title":"High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS)","volume":"109","author":"Fujino","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0042","first-page":"1049","article-title":"Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women","volume":"18","author":"Singhal","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0043","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.jtct.2022.04.011_bib0044","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.04.011_bib0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bmt.2013.232","article-title":"Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib","volume":"49","author":"Mo","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.04.011_bib0046","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.011_bib0047","unstructured":"Center for Internationl Blood and Marrow Transplant. Pre-HCT Preparative Regimen (Conditioning), form 2400. Available at: https:\/\/www.cibmtr.org\/manuals\/fim\/1\/en\/topic\/q155-315-pre-hct-preparative-regimen-conditioning. Accessed March 14, 2022."},{"key":"10.1016\/j.jtct.2022.04.011_bib0048","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:47:51Z","timestamp":1726444071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722012283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666636722012283"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents\/Young Adults With CML in the TKI Era","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}